M N Zhuravlev studies how well treatments work for patients who have had ischemic strokes, which occur when blood flow to the brain is blocked. Their research particularly focuses on a medication called Revelise (alteplase), which is designed to dissolve blood clots. By examining thousands of patients, Zhuravlev aims to understand how this treatment improves recovery and reduces disability among stroke patients, especially the elderly and those with other health issues.
Key findings
In a study involving 2,202 patients, nearly half (49.9%) experienced good outcomes at discharge, indicating significant recovery immediately after treatment.
After 90 days, the proportion of patients with good outcomes rose to 66.4%, showing continued improvement over time.
The study confirmed that Revelise effectively reduces disabilities related to strokes, suggesting it is suitable for patients with varying health conditions.
Frequently asked questions
Does Dr. Zhuravlev study ischemic strokes?
Yes, Dr. Zhuravlev researches treatments for ischemic strokes and how effective they are in helping patients recover.
What treatments has Dr. Zhuravlev researched?
Dr. Zhuravlev has specifically studied thrombolytic therapy using the medication Revelise for treating ischemic strokes.
Is Dr. Zhuravlev's work relevant to elderly patients?
Yes, their research includes a significant number of elderly patients and examines how treatments affect this age group.
Publications in plain English
From DFT to compact non-local model: Accurate and efficient Hückel-based simulation of molecular electronic devices.
2025
The Journal of chemical physics
Shubin NM, Zhuravlev MN, Uspenskii YA, Emelianov AV, Gorbatsevich AA
Plain English This research focused on simplifying the way we study how electrons move through certain molecular devices, like tiny electronic components. The scientists tested different types of molecules with various connections to see how effectively they conducted electricity and found that the connections play a key role in performance. Specifically, they found that certain parameters related to how the molecules communicate with the electrodes are mainly determined by the type of connection, while others depend heavily on the internal structure of the molecule.
Who this helps: This benefits researchers and engineers developing new molecular electronic devices.
[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].
2025
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more
Plain English This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues.
Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.
[Modern problems of stroke at different hospitalization stages based on the data of the Regional Vascular Center of Tyumen].
2019
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Sidorova YK, Doyan YI, Lebedev IA, Zhuravlev MN, Nesterova OA +1 more
Plain English This study looked at how stroke patients are cared for, focusing on what happens before and during their hospital stay. Researchers found that living alone made it harder for patients to get to the hospital quickly, with 58.8% of those affected taking longer to arrive. Additionally, there were many mismatches in diagnoses, with 73.7% of outpatient clinics and 61.9% of other hospitals getting it wrong, which significantly raised the chance of death—from 18.9% to 80% when all three diagnoses disagreed.
Who this helps: This research benefits patients and healthcare providers by highlighting areas for improvement in stroke care.
[Use of mitoxantrone in the treatment of multiple sclerosis].
2009
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Sivertseva SA, Zhuravlev MN, Shmurygina EA, Dekhtiarenko EV, Boĭko AN
Plain English This study looked at the use of a drug called mitoxantrone for treating multiple sclerosis in 30 patients. It found that mitoxantrone significantly reduced the number of flare-ups in patients with relapsing MS and slowed disease progression in those with secondary-progressive MS over an average treatment period of 39 months. The drug was generally well tolerated, but patients need ongoing monitoring for potential long-term side effects.
Who this helps: This benefits patients with multiple sclerosis who are not responding to standard treatments.
[Restoration of voice function in patients without larynx and pharyx: myth or reality?].
2007
Vestnik otorinolaringologii
Novozhilova EN, Zabaznyĭ NP, Zhuravlev MN, Sergeev SA, Burlakov AS +3 more
Plain English This study looked at a new technique for helping people who have lost their ability to speak after surgery to remove their larynx and part of their throat. The researchers found that it's possible to restore voice function in these patients by using prosthetic devices, successfully helping four individuals regain their ability to communicate. This is important because it offers hope and practical solutions for patients with severe voice loss, improving their quality of life.
Who this helps: Patients who have had laryngopharyngectomy and lost their voice.
[Epidemiology of multiple sclerosis in Tiumen' region].
2006
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Sivertseva SA, Zhuravlev MN, Murav'ev SA, Boĭko AN
Plain English This study looked at how many people have multiple sclerosis (MS) in various areas of the Tyumen region, including Tyumen city and the surrounding areas. It found that the overall rate of MS in Tyumen was 22.4 cases per 100,000 people, but it was higher in the southern part of the region at 29.1 per 100,000. Women were more commonly affected than men, with 461 women compared to 270 men in the study, although the ratio of men was higher in some areas.
Who this helps: This research benefits patients, healthcare providers, and public health officials by increasing understanding of MS prevalence in different regions.
[ATPase activity and erythrocyte levels of potassium, sodium, calcium and cholesterol and its fractions and esters in patients in the acute period of cerebral stroke].
1991
Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952)
Klushin DF, Zhuravlev MN, Durova MV
Plain English This study looked at the activity of certain enzymes and the levels of potassium, sodium, calcium, and cholesterol in the red blood cells of 95 patients who had a stroke within the first few weeks. The researchers found that these enzyme activities and mineral levels were significantly different in stroke patients compared to healthy individuals, with changes depending on the type of stroke (reversible or irreversible, ischemic or hemorrhagic). Understanding these differences can help in diagnosing strokes and tailoring treatments based on their specific type.
Who this helps: This helps doctors in treating stroke patients more effectively.